FDA Grants QIDP And Fast Track Designations For Cubist's Late-Stage Antibiotic Candidates

Cubist Pharmaceuticals, Inc.recently announced that the U.S. Food and Drug Administration (FDA) has designated the company’s late-stage antibiotic candidate, ceftolozane/tazobactam, as a Qualified Infectious Disease Product (QIDP) for the indications of Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP) and Complicated Urinary Tract Infections (cUTI).
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news